Toxicity and efficacy of biosimilar bevacizumab in the second-line therapy for metastatic colon cancer in routine clinical practice: results of an independent observational study

Yazar: M.   Yu. Fedyanin, F.   V. Moiseenko, M.   A. Lyadova, V.  N.  Vorobyeva, V.  V.  Petkau, A.  V.  Fateeva, E.  S.  Kuzmina, O.  Yu.  Novikova, V.   A. Chubenko, N.  Kh.  Abduloeva, A.  A.  Kudryavtsev, E.   O. Ignatova, R.   R. Shakirov, O.  A.  Pardabekova, L.  V.  Kindyalova, S.  P.  Pelikh, O.   A. Gladkov, S.  A.  Tjulandin, A.  A.  Tryakin
Baskı/Yayın Bilgisi 2021-06-01